Milestone Pharmaceuticals Announces FDA Acceptance of the Company's Response to the CRL for CARDAMYST™ (etripamil) Nasal SprayGlobeNewsWire • 07/11/25
Watch Milestone Pharmaceuticals For (Likely) Upcoming FDA Approval For CardamystSeeking Alpha • 07/07/25
Milestone Pharmaceuticals Submits Response to the FDA's CRL for CARDAMYST (etripamil) Nasal Spray for PSVT Following Type A MeetingGlobeNewsWire • 06/16/25
Milestone Pharmaceuticals to Present at the Jefferies Global Healthcare ConferenceGlobeNewsWire • 05/28/25
Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate UpdateGlobeNewsWire • 05/14/25
MIST Stock Falls 66% Following Complete Response Letter for CardamystZacks Investment Research • 04/02/25
Milestone Pharmaceuticals: A Compelling Value Proposition For Patients And PayersSeeking Alpha • 03/21/25
Milestone Pharmaceuticals to Present Clinical Data on Etripamil at the American College of CardiologyGlobeNewsWire • 03/20/25
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate UpdateGlobeNewsWire • 03/13/25
Milestone® Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care ConferenceGlobeNewsWire • 02/27/25
Milestone® Pharmaceuticals Notice of Allowance on New U.S. Patent for EtripamilGlobeNewsWire • 02/19/25
Milestone Pharmaceuticals to Host Commercial Launch Plan Investor Event in New York on February 25, 2025GlobeNewsWire • 02/11/25
Milestone Pharmaceuticals Provides 2025 Corporate Outlook and Will Host Investor Event on February 25 in NYCGlobeNewsWire • 01/28/25
After Golden Cross, Milestone Pharmaceuticals (MIST)'s Technical Outlook is BrightZacks Investment Research • 11/19/24
Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate UpdateGlobeNewsWire • 11/12/24
Milestone Partner Ji Xing Pharmaceuticals Ltd Announces Positive Topline Results from the Phase 3 Study of Etripamil in PSVT in ChinaGlobeNewsWire • 09/06/24
Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of DirectorsGlobeNewsWire • 09/04/24
Milestone Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Regulatory and Corporate UpdateGlobeNewsWire • 08/08/24
Milestone Pharmaceuticals to Host KOL Event for Investors “Learnings from the Field: Expert Perspectives on PSVT in the Community Setting” on June 20, 2024GlobeNewsWire • 06/12/24